Extended Data Fig. 1: Survival outcomes in cohort 4B and exploratory analysis cohort 4A + 4B in the safety analysis set. | Nature Medicine

Extended Data Fig. 1: Survival outcomes in cohort 4B and exploratory analysis cohort 4A + 4B in the safety analysis set.

From: First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Extended Data Fig. 1: Survival outcomes in cohort 4B and exploratory analysis cohort 4A + 4B in the safety analysis set.

a, Kaplan-Meier curves of PFS in all patients. b, Kaplan-Meier curves of PFS by CLDN18.2 expression. c, Kaplan-Meier curves of PFS in patients in cohort 4A + 4B with high CLDN18.2 expression by PD-L1 CPS. d, Kaplan-Meier curves of OS by CLDN18.2 expression. PFS was assessed by investigators per RECIST v1.1. PFS and OS were estimated using the Kaplan-Meier method with corresponding 95% CIs. One patient was missing a value for CLDN18.2 expression. Two patients were missing PD-L1 CPS values. Cohort 4 A had no patients with intermediate CLDN18.2 expression, and therefore cohorts 4 A + B and 4B are identical. CLDN18.2, claudin 18 isoform 2; CPS, combined positive score; OS, overall survival; PFS, progression-free survival; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1.

Back to article page